Insiders Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:10:07 20/05/2026 BST			5-day change	1st Jan Change
14.00 ^AUD	-1.48%		-2.98%	+25.00%

05-15	Telix to Collaborate With EDAP, Profound Medical to Explore PSMA-PET Imaging in Prostate Cancer Therapies	MT
05-15	Telix announces collaborations to explore PSMA-PET imaging in emerging prostate cancer treatment approaches	RE

Insiders

05-07	Telix Pharmaceuticals Insider Bought Shares Worth $996,738, According to a Recent SEC Filing	MT
04-09	Telix Pharmaceuticals Limited Announces Board Appointments, Effective May 11, 2026	CI
04-02	Telix Pharmaceuticals Limited Appoints David Gill as Non-Executive Director, Effective May 11, 2026	CI
02-02	Telix Pharmaceuticals Chair Resigns	MT
02-02	Telix Pharmaceuticals says Mark Nelson appointed interim chair	RE
02-02	Telix Pharmaceuticals Limited Announces Board Changes	CI
28/04/25	Telix Pharmaceuticals Limited Announces Resignation of Anne Whitaker from its Board, Effective 29 April 2025	CI
07/04/25	Telix Appoints Paul Schaffer As Chief Technology Officer	RE
07/04/25	Telix Pharmaceuticals Appoints Chief Technology Officer	MT
07/04/25	Telix Pharmaceuticals Limited Appoints Paul Schaffer as Chief Technology Officer, Effective April 6, 2025	CI
03/04/25	Telix Pharmaceuticals Limited Announces Appointment of Anne Whitaker as A Non-Executive Director Based in the United States, Effective 7 April 2025	CI
26/02/25	Telix Pharmaceuticals Says Tiffany Olson To Be Appointed Board Chair	RE
26/02/25	Telix Pharmaceuticals Names New Board Chair	MT
25/02/25	Telix Pharmaceuticals Limited Announces Board Renewal	CI
17/10/24	Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors	CI
27/08/24	Telix Pharmaceuticals Reorganizes Top Management for New Strategy	MT
27/08/24	Telix Pharmaceuticals Limited Announces Executive Changes	CI
25/03/24	Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent	CI
11/03/24	Telix Pharmaceuticals Appoints Group COO; Shares Down 4%	MT
20/12/23	Telix Pharmaceuticals Appoints Group Medical Chief	MT
19/12/23	Telix Pharmaceuticals Limited Announces Executive Changes	CI
04/12/23	Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent	CI
28/03/23	Telix Pharmaceuticals Limited Grants Andreas Kluge a Leave of Absence from his Role as Non-Executive Director	CI
05/12/22	Telix Pharmaceuticals Appoints Chief Commercial Officer	MT
04/12/22	Telix Pharmaceuticals Limited Announces Leadership Changes	CI